P1, N=85, Recruiting, Medical University of Vienna

P=N/A, N=120, Recruiting, Northwell Health

P4, N=400, Recruiting, The Chaim Sheba Medical Center | Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2027

To overcome this issue, herein, we developed a cobalt-pheophytin (CoPheo) coordination micelle chelating two chemotherapeutic agents including ONC201 and Palbociclib (Pal), yielding CoPheo-ONC201-Pal-F127. In addition, ONC201-mediated mitogen-activated protein kinase kinase (MEK) inhibition, combined with Pal-induced CDK4/6 blockade, promotes cellular senescence and remodels the tumor microenvironment. These three independent mechanisms collectively establish a mutually enhanced therapeutic strategy capable of overcoming the complex drug resistance driven by multiple downstream signaling pathways in KRAS-mutant pancreatic cancer.

P2, N=46, Completed, Hasanuddin University

P1, N=12, Recruiting, Engrail Therapeutics INC

P2, N=150, Recruiting, Tanta University | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

Our results highlight ONC206 as a novel therapeutic option for patients with high-risk medulloblastoma and provide strong rationale for testing the efficacy of ONC206 in the treatment of these patients.

Conversely, compared with those of the model group, the expression of NPY, SOCS3, NLRP3, ASC, cleaved caspase-1, GSDMD-N, and IL-1β was significantly downregulated, and the expression of POMC and LEPR was significantly upregulated in the medium-and high-dose HLWDD groups and the metformin group. These results collectively indicate that HLWDD ameliorates olanzapine-induced feeding dysregulation by mitigating leptin resistance through suppression of NLRP3-driven neuroinflammatory pathways in the arcuate nucleus.

P3, N=70, Recruiting, University of Sao Paulo General Hospital

P2/3, N=80, Completed, Intra-Cellular Therapies Inc. | Recruiting --> Completed

Treatments included the anti-CD20 mAb rituximab, anti-ROR1 mAbs (GE-zilovertamab, zilovertamab), and the endocytosis inhibitor prochlorperazine, and ADCC was quantified. We find that the endocytosis inhibitor prochlorperazine further increased this effect. GE-zilovertamab is a promising next-generation immunotherapeutic for CLL, combining selective targeting of ROR1 with the potential to reduce therapy-induced immunodeficiency compared with anti-CD20 antibodies.